DDW: Serum HBsAg Levels & serum HBV DNA

StephenW

	Abstract:	Su1014 Year: 2011
	Title:	Serum Hepatitis B Surface Antigen Levels Correlates Well with Serum HBV DNA Levels in Patients with Chronic Hepatitis B: A Cross Sectional Study
	Author:	Ekta Gupta1, Ashish Kumar2, Aashish Choudhary1, Sandeep Tyagi1, Shiv Kumar Sarin2
	Topic:	Viral Hepatitis
	Abstract:	Background: Measurement of serum hepatitis B virus (HBV) DNA levels is an integral part in diagnosis and monitoring of patients of chronic hepatitis B. Commercially available HBV DNA assays lack standardization and uniformity, are cumbersome needing high expertise and very expensive. Recent studies have suggested that quantitative serum hepatitis B surface antigen (HBsAg) levels can be used in place of HBV DNA levels to monitor treatment outcome. However, the data correlating HBV DNA levels with HBsAg levels are scarce. Aim: To correlate HBV DNA levels with HBsAg levels in patients with chronic HBV infection. Patients and Methods: Consecutive patients of chronic HBV infection (both naïve and on-treatment) attending the out-patient clinic of Institute of Liver & Biliary Sciences (ILBS) were included. Patients with undetectable HBV DNA levels were excluded. HBV DNA quantitation was done on patient’s plasma (500µl) on COBAS TaqMan HBV test with high pure extraction (Roche Diagnostics) as per the manufactures protocol. Results were expressed as IU/ml. Lower limit of detection for the assay is 6 IU/ml and linear range 29 to 1.1×108 IU/ml. HBsAg levels were done by the Architect HBsAg QT (Abbott) assay as per the manufactures protocol and results were expressed as IU/mL. Non-parametric two-tailed Spearman’s test was used to correlate HBV DNA and HBsAg levels. Results: A total of 73 patients were included in the study (mean age 43±14 years, 82% males). Of them 43 (59%) were treatment-naïve and 30 (41%) were on treatment with antiviral drugs. Thirty-four (47%) were HBeAg positive and rest were negative. Fifty-seven (78%) patients were chronic hepatitis and rest had cirrhosis. The median HBV DNA level was 104 (range 10 to 108) IU/mL. Forty-three (59%) patients had high HBV DNA levels (≥2000 IU/mL). The median HBsAg level was 12752 (range 5 to 125000) IU/mL. There was significant correlation between HBV DNA levels and HBsAg levels (Spearman’s rho 0.458, p value <0.001). On receiver operating characteristics curve the area under the curve for HBsAg level for diagnosing high HBV DNA level was 0.762 (95% CI 0.653, 0.872; p<0.01) (Figure). Conclusions: Serum HBsAg levels correlates well with serum HBV DNA levels in patients with chronic Hepatitis B. Serum HBsAg level can reliably used for diagnosing high HBV DNA level.
	Disclosure:	The following people have nothing to disclose: Ekta Gupta, Ashish Kumar, Aashish Choudhary, Sandeep Tyagi, Shiv Kumar Sarin

StephenW

谷歌翻译不是100％准确，仅供参考。

背景：血清乙型肝炎病毒（HBV）DNA水平的测量是在市售的HBV DNA检测缺乏标准化和统一性，是繁琐的需要很高的专业知识和非常昂贵的慢性乙型肝炎患者的诊断和监测的组成部分。最近的研究表明，定量血清乙肝表面抗原（HBsAg）的水平，可用于监测治疗结果HBV DNA水平发生。然而，数据关联与HBsAg水平的HBV DNA水平也非常有限。
目的：关联与HBsAg水平与慢性HBV感染患者的HBV DNA水平。
病人及方法：患者的慢性HBV感染者（既天真又在治疗），肝及胆道科学研究所（ILBS）出席科门诊诊所。与检测不到HBV DNA水平的患者被排除在外。 HBV DNA定量COBAS TaqMan探针HBV高纯度提取（罗氏诊断）测试病人的血浆（500μL）按照生产协议。结果表示为IU / ml的。更低的检测限为检测6 IU / ml和线性范围为29至1.1 × 108 IU /毫升。由建筑师HBsAg的QT（雅培）检测HBsAg水平，为制造商协议和结果表示IU / mL的。非参数双尾斯皮尔曼的测试是用于关联HBV DNA和HBsAg水平。
结果：共纳入研究的73例（平均年龄43 ± 14岁，82％的男性）。其中43个（59％）治疗初治和30（41％）与抗病毒药物治疗。第三个（47％）为HBeAg阳性和其余均为阴性。五十七名患者（78％），慢性肝炎和休息了肝硬化。中位数的HBV DNA水平为104（范围从10到108）IU /毫升。四十三（59％）患者的HBV DNA水平高（≥2000 IU / mL）的。 HBsAg水平中位数为12752（范围5〜125000）IU / mL的。 HBV DNA水平和HBsAg水平之间有显着相关（斯皮尔曼的RHO 0.458，P值<0.001）。接受者操作特性曲线的乙肝表面抗原诊断HBV DNA水平高的水平曲线下面积为0.762（95％CI：0.653，0.872，P <0.01）（图）。
结论：血清HBsAg水平在与慢性乙型肝炎血清HBsAg水平患者血清HBV DNA水平相关联，可以可靠地用于诊断HBV DNA水平高。